Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24317467 | 0.90 | OPRD1 (0.50) | OPRD1RAB9A | |
| SCHEMBL26619435 | 0.85 | SIGMAR1 (0.50) | OPRD1SIGMAR1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL24317470 | 0.85 | ADRA2A (0.44) | OPRD1SIGMAR1 | |
| SCHEMBL13061105 | 0.82 | SIGMAR1 (0.43) | OPRD1SIGMAR1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL13061092 | 0.82 | SIGMAR1 (0.43) | OPRD1SIGMAR1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL24315726 | 0.82 | OPRD1 (0.46) | OPRD1SIGMAR1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL13005567 | 0.78 | SIGMAR1 (0.40) | OPRD1SIGMAR1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL13005578 | 0.78 | SIGMAR1 (0.40) | OPRD1SIGMAR1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL12125006 | 0.78 | — | — | |
| SCHEMBL10684415 | 0.77 | SLC18A2 (0.61) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022081927-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |